ICP
AZN icon

Impact Capital Partners’s AstraZeneca AZN Stock Holding History

Impact Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$323K Sell
1,705
-51
-3% -$9.59K 0.09% 199
2026
Q1 		$346K Sell
1,756
-6
-0.3% -$1.16K 0.1% 192
2025
Q4 		$324K Buy
1,762
+19
+1% +$3.33K 0.1% 205
2025
Q3 		$267K Buy
1,743
+102
+6% +$15.4K 0.08% 230
2025
Q2 		$229K Buy
1,641
+222
+16% +$31.1K 0.08% 248
2025
Q1 		$209K Buy
+1,419
New +$205K 0.08% 247

Other funds holding AZN

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return
ZIC
ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return
AIM
Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return
CAM
Cidel Asset Management Toronto, Ontario, Ontario, Canada $2.08B AUM 24.89% 1-Year Est. Return
MBI
Montrusco Bolton Investments Montreal, Quebec, Canada $6.46B AUM 26.7% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return

Impact Capital Partners's AZN Position: Q2 2026 in Review

Impact Capital Partners reduced its AstraZeneca (AZN) stake by 2.9% in Q2 2026, selling an estimated $9.59K and leaving 1,705 shares worth $323K. The position accounts for 0.09% of the portfolio, ranked #199.

Impact Capital Partners first reported a position in AZN in Q1 2025 and has held it in 6 quarters since. The position peaked at $346K in Q1 2026. 351 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Impact Capital Partners held 1,705 shares of AstraZeneca worth $323K as of Q2 2026.
  • Impact Capital Partners sold 51 AstraZeneca shares in Q2 2026, an estimated $9.59K.
  • AstraZeneca made up 0.09% of Impact Capital Partners's portfolio in Q2 2026, its #199 holding.
  • Impact Capital Partners first reported a position in AstraZeneca in Q1 2025 and has held it in 6 quarters since.
  • Impact Capital Partners's AstraZeneca position peaked at $346K in Q1 2026.
  • 351 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Impact Capital Partners's 13F filing for Q2 2026, filed 14 Jul 2026.